Revised Pact With Pfizer Offers Eye Delivery Specialist pSivida Flexibility
This article was originally published in The Pink Sheet Daily
Changes to the agreement between pSivida and Pfizer will allow the drug delivery specialist to scout out other partnership opportunities, firm says.
You may also be interested in...
The ophthalmology company received a “complete response” for lead product Iluvien.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.